Cullinan Associates’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.8M Sell
46,424
-4,807
-9% -$429K 0.36% 62
2026
Q1
$3.68M Buy
51,231
+3,844
+8% +$296K 0.3% 69
2025
Q4
$3.76M Sell
47,387
-893
-2% -$70.4K 0.25% 74
2025
Q3
$3.64M Buy
48,280
+813
+2% +$55.7K 0.24% 78
2025
Q2
$3.27M Buy
47,467
+3,008
+7% +$197K 0.22% 82
2025
Q1
$3.01M Buy
44,459
+4,841
+12% +$290K 0.21% 88
2024
Q4
$1.78M Sell
39,618
-83,064
-68% -$4.66M 0.11% 113
2024
Q3
$7.12M Buy
122,682
+37,395
+44% +$2.18M 0.4% 56
2024
Q2
$5.04M Sell
85,287
-34,210
-29% -$2.14M 0.29% 71
2024
Q1
$9.53M Buy
119,497
+11,444
+11% +$874K 0.53% 47
2023
Q4
$8.53M Sell
108,053
-41,162
-28% -$2.93M 0.48% 50
2023
Q3
$10.4M Sell
149,215
-14,575
-9% -$1.03M 0.61% 40
2023
Q2
$11.3M Sell
163,790
-31,753
-16% -$2.26M 0.62% 43
2023
Q1
$14.5M Buy
195,543
+5,426
+3% +$455K 0.85% 31
2022
Q4
$17.7M Buy
190,117
+2,569
+1% +$248K 0.98% 21
2022
Q3
$17.9M Buy
187,548
+4,167
+2% +$412K 1.13% 18
2022
Q2
$17M Buy
183,381
+11,213
+7% +$1.09M 1.04% 22
2022
Q1
$17.4M Buy
172,168
+2,399
+1% +$252K 0.91% 26
2021
Q4
$17.5M Buy
169,769
+16,488
+11% +$1.52M 0.89% 29
2021
Q3
$13M Buy
153,281
+10,605
+7% +$888K 0.72% 38
2021
Q2
$11.9M Buy
142,676
+28,917
+25% +$2.37M 0.67% 44
2021
Q1
$8.56M Buy
113,759
+2,261
+2% +$165K 0.49% 59
2020
Q4
$7.62M Sell
111,498
-8,787
-7% -$572K 0.46% 62
2020
Q3
$7.03M Buy
120,285
+3,939
+3% +$245K 0.45% 56
2020
Q2
$7.56M Sell
116,346
-527
-0.5% -$33.2K 0.53% 42
2020
Q1
$6.93M Buy
116,873
+3,402
+3% +$227K 0.57% 49
2019
Q4
$8.43M Buy
113,471
+8,112
+8% +$570K 0.56% 46
2019
Q3
$6.64M Buy
105,359
+17,047
+19% +$1.01M 0.47% 61
2019
Q2
$4.81M Buy
88,312
+4,818
+6% +$259K 0.35% 81
2019
Q1
$4.5M Sell
83,494
-8,630
-9% -$533K 0.34% 86
2018
Q4
$6.04M Buy
92,124
+1,209
+1% +$90.2K 0.5% 50
2018
Q3
$7.16M Buy
90,915
+3,006
+3% +$215K 0.52% 53
2018
Q2
$5.66M Buy
87,909
+12,001
+16% +$791K 0.43% 68
2018
Q1
$4.72M Sell
75,908
-32,167
-30% -$2.31M 0.36% 82
2017
Q4
$7.83M Sell
108,075
-10,593
-9% -$770K 0.58% 42
2017
Q3
$9.65M Buy
118,668
+3,498
+3% +$277K 0.74% 38
2017
Q2
$9.27M Buy
115,170
+10,060
+10% +$794K 0.72% 41
2017
Q1
$8.25M Buy
105,110
+49,400
+89% +$3.94M 0.67% 40
2016
Q4
$4.4M Buy
55,710
+480
+0.9% +$38.8K 0.37% 73
2016
Q3
$4.92M Hold
55,230
0.42% 68
2016
Q2
$5.29M Buy
55,230
+50
+0.1% +$4.98K 0.43% 63
2016
Q1
$5.72M Buy
55,180
+1,000
+2% +$97.2K 0.49% 56
2015
Q4
$5.3M Buy
54,180
+16,010
+42% +$1.57M 0.46% 53
2015
Q3
$3.68M Buy
38,170
+850
+2% +$89.4K 0.34% 67
2015
Q2
$3.91M Sell
37,320
-5,900
-14% -$603K 0.32% 76
2015
Q1
$4.46M Sell
43,220
-1,940
-4% -$196K 0.35% 64
2014
Q4
$4.35M Buy
45,160
+7,205
+19% +$635K 0.46% 37
2014
Q3
$3.02M Buy
37,955
+5,280
+16% +$416K 0.34% 46
2014
Q2
$1.87M Sell
32,675
-3,000
-8% -$227K 0.3% 45
2014
Q1
$2.67M Sell
35,675
-200
-0.6% -$14.1K 0.3% 48
2013
Q4
$2.57M Sell
35,875
-2,500
-7% -$161K 0.3% 48
2013
Q3
$2.18M Buy
38,375
+3,000
+8% +$179K 0.29% 48
2013
Q2
$2.02M Buy
+35,375
New +$2.05M 0.27% 49

Other funds holding CVS

Cullinan Associates's CVS Position: Q2 2026 in Review

Cullinan Associates reduced its CVS Health (CVS) stake by 9.4% in Q2 2026, selling an estimated $429K and leaving 46,424 shares worth $4.8M. The position accounts for 0.36% of the portfolio, ranked #62.

Cullinan Associates first reported a position in CVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $17.9M in Q3 2022. 2,061 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • Cullinan Associates held 46,424 shares of CVS Health worth $4.8M as of Q2 2026.
  • Cullinan Associates sold 4,807 CVS Health shares in Q2 2026, an estimated $429K.
  • CVS Health made up 0.36% of Cullinan Associates's portfolio in Q2 2026, its #62 holding.
  • Cullinan Associates first reported a position in CVS Health in Q2 2013 and has held it in 53 quarters since.
  • Cullinan Associates's CVS Health position peaked at $17.9M in Q3 2022.
  • 2,061 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on Cullinan Associates's 13F filing for Q2 2026, filed 29 Jul 2026.